Newsroom :: CytoDyn Inc. (CYDY)

For the latest results and updates on our Phase 2 CRC trial and more, here’s a direct link to our October 19, 2026 Investor Update Webinar

Learn More

CytoDyn Announces Encouraging Survival Data in Patients with Metastatic Colorectal Cancer Previously Treated with Leronlimab

Jul 01, 2025 8:30am EDT

CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer

Jun 24, 2025 8:30am EDT

CytoDyn Releases ESMO Breast Cancer Meeting Poster

May 15, 2025 8:30am EDT

CytoDyn Announces Data Suggesting Novel Mechanism of Action of Leronlimab for the Treatment of Solid Tumors

May 13, 2025 8:30am EDT

CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer

May 06, 2025 8:30am EDT

CytoDyn Leadership Team To Attend ESMO Breast Cancer Meeting in Munich, Germany

Apr 29, 2025 8:30am EDT

March 2025 Letter to Shareholders

Mar 18, 2025 8:30am EDT

CytoDyn Announces Promising Survival Observations in mTNBC Patients Treated with Leronlimab

Feb 24, 2025 8:30am EST

CytoDyn Announces Findings of Statistically Significant Fibrosis Reversal Across Studies with SMC Laboratories

Feb 06, 2025 8:30am EST

December 2024 Letter to Shareholders

Dec 17, 2024 8:30am EST

1
2
3
4
5
6
7
8